IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their clinical trials will take place in premier investigative research centers with recognized professionals and with infrastructure focused on innovation and research development for patients.
LMC Manna and IQVIA will collaborate on research programs to optimize processes, reduce the time to start clinical research, align procedures and support a significant increase in complex clinical and real-world evidence studies in Canada.
“Our partnership with LMC Manna Research leverages a strong infrastructure and transformational technologies to bring research to communities across Canada,” said Richard Staub, president, Research and Development Solutions, IQVIA.
LMC Manna Research is the largest wholly owned integrated research network in Canada, conducting phases I-IV studies at 22 trial sites across three provinces with access to well over 500,000 patients. IQVIA will provide staff dedicated to LMC Manna Research, including a prime site manager who will oversee partnership relations and follow up on the delivery of IQVIA research projects.
“We are excited to partner with IQVIA to co-develop strategies to improve clinical research in Canada and globally,” said Karri Venn, president, Research at LMC Manna Research. “Our common commitment to bring meaningful research to patients while improving the entire continuum is magnified and made more tangible through this partnership. We look forward to collaborating across multiple domains to bring improvement to clinical research to both Canadians and the industry.”
IQVIA is committed to expanding research globally through strong site relations and partnerships. For more information, visit https://www.iqvia.com/solutions/research-and-development/clinical-trials.
IQVIA (NYSE: IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Tor Constantino, IQVIA Media Relations (firstname.lastname@example.org)
Andrew Markwick, IQVIA Investor Relations (email@example.com)